<div class="p4l_caption"><div class="p4l_captionTitle"><a target="_blank" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063194/" ref="ordinalpos=3400&amp;ncbi_uid=2844022&amp;link_uid=PMC3063194" image-link="/pmc/articles/PMC3063194/figure/F1/" class="imagepopup">Figure 1.  From: Innate immune modulation in EBV infection. </a></div><br /><div class="p4l_captionBody"><b>Elicitation of innate immune response in EBV infection</b>. EBV dUTPase and GP350 act as ligands for TLR2. EBV EBERs can mount innate immune responses via both TLR3 and RIG-I signaling pathways. Infection of EBV also activates TLR9 signaling leading to IFNÎ± production in pDCs. In latency, EBV manipulates the TLR7/IRF5 signaling pathway, which promotes cell proliferation. EBV products are indicated in red fonts.</div></div>